{"title":"当慢性病和罕见病的世界交汇在一起","authors":"Asher Mullard","doi":"10.1038/d41573-024-00114-3","DOIUrl":null,"url":null,"abstract":"Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology. Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 9","pages":"654-655"},"PeriodicalIF":101.8000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"When chronic and rare disease worlds converge\",\"authors\":\"Asher Mullard\",\"doi\":\"10.1038/d41573-024-00114-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology. Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology.\",\"PeriodicalId\":19068,\"journal\":{\"name\":\"Nature Reviews. Drug Discovery\",\"volume\":\"23 9\",\"pages\":\"654-655\"},\"PeriodicalIF\":101.8000,\"publicationDate\":\"2024-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews. Drug Discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/d41573-024-00114-3\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews. Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/d41573-024-00114-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology. Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology.
期刊介绍：
Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena.
Each issue includes:
Highest-quality reviews and perspectives covering a broad scope.
News stories investigating the hottest topics in drug discovery.
Timely summaries of key primary research papers.
Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
